A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Ofatumumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms MIRROR
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 28 Apr 2017 Results presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 22 Mar 2015 Status changed from active, no longer recruiting to completed.
    • 16 Oct 2014 Planned End Date changed from 1 May 2016 to 1 Jun 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top